To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Amendment to Purchase Order with Qiagen LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, an amendment to purchase order #30831 with Qiagen, LLC to increase the payment limit by $2,000,000 to a new amount not to exceed $2,800,000 for the purchase of reagents and medical supplies including QuantiFERON - Tuberculosis (TB) and AmniSure products for the Clinical Laboratory at the Contra Costa Regional Medical Center (CCRMC), and extend the term through May 31, 2029.
FISCAL IMPACT:
Approval of this action will result in expenditures of up to $2,800,000 over a five-year period and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
CCRMC Clinical Laboratory Department utilizes Qiagen, LLC for reagents and supplies for QuantiFERON Tuberculosis (TB) and AmniSure testing. The CCRMC Clinical Lab has seen a dramatic increase in tuberculosis testing due to changes in the Centers of Disease Control and Prevention (CDC) and State of California regulations for QuantiFERON TB testing. The Clinical lab has expended its available funds quicker than originally anticipated with the regulatory changes prompting over 40% increase year over year in testing of QuantiFERON. Once this was realized, the lab met with Qiagen to review its usage and is requesting an additional $2,000,000 in funds to meet the laboratory’s current usage, along with extending the current purchase order end date to May 31, 2029 (from original date May 31, 2027) with no change in pricing resulting in significant cost savings for the county.
On August 6, 2024 the Board of Supervisors approved agenda item C.53 to execute a Purchase Order with Qiagen, LLC and Master Purchasing Agreement for the purchase of medical supplies including QuantiFERON - Tuberculosis (TB) and AmniSure products for the clinical laboratory and health centers over a three-year period from June 1, 2024 through May 31, 2027 for $800,000. On March 18, 2026 the Purchasing Agent approved the continued use of Qiagen, LLC.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, the CCRMC Clinical Laboratory Department will not have access to this vendor’s specific patient testing supplies and reagents, thus impacting patient safety and health.